You are using an outdated browser. Please upgrade your browser to improve your experience.

Our views 03 February 2026

SustainAbility: The healthy theme

2 min read

At Royal London Asset Management our sustainable funds are built around four core sustainability themes: Clean, Healthy, Safe, and Inclusive. We seek out companies that make a positive contribution to one or more of these themes, both through what they offer (their products and services) and how they operate.

To qualify, at least half of a company’s revenues must come from activities aligned with these sustainability themes. The aim of this thematic approach is to ensure that our investments are financially robust, while supporting a more sustainable future. 

The ‘healthy’ theme 

Our health is at the heart of all our lives, but it’s increasingly at the heart of our economy as well. Most developed countries spend over 10% of their GDP on healthcare, and healthcare companies make up around 9% of global stock market indices. 

Our health is at the heart of all our lives, but it’s increasingly at the heart of our economy as well.

You might be forgiven for thinking that healthcare companies solely focus on selling medicines. Innovation into new therapies and treatments is complemented by companies focused on improving access to healthcare and making these medicines more affordable. However, pharmaceuticals are only one piece of the puzzle. 

From the operations room (where your surgeon might well be accompanied by a robot) to the processing room that sterilises instruments, our businesses can be found supporting hospitals in providing care to patients. And some are involved behind the scenes, providing the equipment, tools and services which help to bring new medicines from a molecule brimming with potential, to a blockbuster drug.  

Why ‘healthy’ companies can make good investments 

Although spending on healthcare dipped after the exceptional growth experienced during the pandemic, over the long-term demand for healthcare continues to grow. Scientific discoveries have helped us to deliver new and exciting medicines, but just as important has been the step up in life expectancy. Improvements in our health during early and working-age life mean more of us now live longer, and as we reach old age our demand for healthcare both to pre-empt disease, and treat it, rises. Companies which benefit from these trends can reap the benefit from successful research and development and tend to offer durable long-term growth. 

CASE STUDY

Thermo Fisher

  • Healthcare
  • Life sciences
  • Diagnostics

A global leader in life sciences, Thermo Fisher is a one-stop shop for the healthcare industry. With more than 400,000 customers, from biotech startups and leading universities to hospitals and diagnostic labs, the company offers its customers a wide range of tools, instruments and services to solve almost any challenge in healthcare. 

The firm’s specialty diagnostics division helps more to accurately and efficiently identify diseases, while the analytical instruments division offers tools and services to customers researching and developing new medicines. And once a disease is identified and a molecule created, the company has solutions to help produce the drug at scale and carry out the clinical trials required to ensure that a treatment is both safe and effective.  

Our analysis suggests that in every division, Thermo Fisher’s revenues are well aligned with the aim of making the world a healthier place and so deserves inclusion in our sustainable funds.  

 

For professional investors only. This material is not suitable for a retail audience. Capital at risk. This is a financial promotion and is not investment advice. Past performance is not a guide to future performance. Reference to any security is for information purposes only and should not be considered a recommendation to buy or sell.

The value of investments and any income from them may go down as well as up and is not guaranteed. Investors may not get back the amount invested. Portfolio characteristics and holdings are subject to change without notice. The views expressed are those of the author at the date of publication unless otherwise indicated, which are subject to change. Forward looking statements are subject to certain risks and uncertainties,  Actual outcomes may be materially different from those expressed or implied.